Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

The global Biopharmaceutical CDMO market size is projected to grow from US$ 27,550 Million in 2024 to US$ 59,300 Million in 2030; it is expected to grow at a CAGR of 13.6% from 2024 to 2030.

ReportPrime' newest research report, the “Biopharmaceutical CDMO Industry Forecast” looks at past sales and reviews total world Biopharmaceutical CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Biopharmaceutical CDMO sales for 2023 through 2029.

This Insight Report provides a comprehensive analysis of the global Biopharmaceutical CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceutical CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type

• Cell and Gene Therapies
• Antibodies
• Vaccines
• Other

Segmentation by Application

• SMBs
• Large Companies

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage

• Lonza
• Catalent
• Samsung Biologics
• FUJIFILM Diosynth Biotechnologies
• Boehringer Ingelheim
• WuXi AppTech
• Recipharm
• Thermo Fisher Scientific
• AGC Biologics
• Rentschler Biopharma
• KBI Biopharma
• Siegfried
• Aenova Group
• GenScript
• ProBioGen
• Northway Biotech
• 3P Biopharmaceuticals

Key Questions Addressed in this Report